|
Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
Our report gives you the following advantages:That mix of quantitative and qualitative market analysis sets our report apart. Our independent analysis helps you to stay ahead in commercial knowledge. Order our report now to gain industry and market information you need Our report can benefit everybody interested in pharmaceutical wholesaling and distribution. We give predictions and answers you need. Don't miss out - please order our report now. Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6 180 seiten | |||||||||||
| Inhalt der Studie: |
How will the pharma wholesale and distribution industry perform from 2011 onwards? Our new report shows you that industry and market's revenue potential from 2011 to 2021.
There, you will assess th.....
How will the pharma wholesale and distribution industry perform from 2011 onwards? Our new report shows you that industry and market's revenue potential from 2011 to 2021. There, you will assess the trends and opportunities shaping the pharmaceutical distribution chain. We aim to save you time and aid your decisions through our research, analysis and discussions. Our report shows you revenue prospects for pharmaceutical wholesale and distribution activities at total world, company and national levels. We forecast revenues of McKesson (US), Cardinal Health (US), AmerisourceBergen (US), The Phoenix Group (Europe), Celesio (Europe), Alfresa Holdings (Japan), Medipal (Japan), Alliance Boots (Europe) and Suzuken (Japan). You will discover their prospects to 2021. What effects will healthcare budget cuts have on pharmaceutical wholesalers? Which national markets will provide the best opportunities from 2011 to 2021? How common will direct-to-pharmacy distribution become? Our work provides answers you need. We help you to assess the pharma wholesale and distribution industry's strengths, weaknesses, trends and revenue opportunities to 2021. You will see where the industry and market are heading. Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now. Industry and market analysis to help your work - so you won't be left behind Our report gives you revenue forecasts, growth rates and market shares. We also provide a SWOT/STEP review, analysis of companies and external opinions from our industry survey. We include 117 tables and charts and two research interviews (shown in the accompanying lists). Our study helps you to understand pharma wholesaling and distribution this decade Report Highlights Companies Listed Acofarma (Asociación Cooperativas Farmacéuticas) [Spain] Alfresa Holdings and its subsidiaries: Alfresa Alfresa Medical Service Alfresa Nikken Sangyo Ando Co CS Yakuhin Co Kowa Pharmaceuticals Co Meisho Co Odashima Ryuyaku Co Seiwa Sangyo Co Shikoku Alfresa Alliance Boots and its subsidiaries: Alliance Healthcare Alloga Almus Pharmaceuticals Andreae-Noris Zahn (ANZAG) [Germany] Cordia Healthcare Galenica Hedef Alliance Holding HydraPharm [Algeria] Megapharm [Germany] UCP [Egypt] AmerisourceBergen and its subsidiaries: American Health Packaging Anderson Packaging Brecon Pharmaceuticals Astellas Pharma AstraZeneca Athos Farma Australian Pharmaceutical Industries Barr Pharmaceuticals (now part of Teva Pharmaceuticals) Bayer Bristol-Myers Squibb British Association of Pharmaceutical Wholesalers (BAPW) Bundesverband des Pharmazeutischen Grosshandel (PHAGRO) [Germany] Cardinal Health and its subsidiaries: Kinray MediCap Pharmacy Medicine Shoppe International Zuellig Pharma China (Yong Yu) CareFusion Celesio and its subsidiaries: AAH Pharmaceuticals [UK] Admenta Italia [Italy] Cahill May Roberts [Ireland] Evolution Homecare [UK] GEHE [Germany] GEHE Pharma Praha [Czech Republic] Herba Chemosan [Austria] Inten [Germany] Kemofarmacija [Slovenia] Laboratoria Flandria [Belgium] Norsk Medisinaldepot [Norway] OCP [France/Portugal] Panpharma [Brazil] Pharma Belgium [Belgium] Pharmactiv [France] Tjellesen Max Jenne [Denmark] Vitapharm [Slovenia] Center for Medicine in the Public Interest [US] CERP France (CERP Bretagne Nord, CERP Rhin Rhone Mediterranee and CERP Rouen) Chambre Syndicale de la Répartition Pharmaceutique (CSRP) [France] China Health Systems China National Pharmaceutical Group (Sinopharm) Cofares Hefame (formerly Cofares and Hefame) CVS Caremark (formerly CVS and Caremark Rx) Department of Health [UK] Eli Lilly European Association of Euro-Pharmaceutical Companies (EAEPC) European Federation of Pharmaceutical Industries and Associations (EFPIA) GlaxoSmithKline (GSK) Guangzhou Pharmaceuticals Healthcare Distribution Management Association (HDMA) [US] Hubei Kyoso Pharmaceutical (a Toho and Jointown joint venture) Humana Johnson & Johnson (J&J) Japanese Pharmaceutical Wholesalers Association (JPWA) Jointown Pharmaceutical Group Katren KL Holding Kohlberg Kravis Roberts & Co (KKR) McKesson and its subsidiaries: Nadro Oncology Therapeutics Network Parata Systems US Oncology Medco Health Solutions Medipal and its subsidiaries: Atol Co Chiyaku Co Everlth Co Izutsu Pharmaceutical Co Kobashou Co Kuraya Sanseido (now Mediceo) Heisei Yakuhin Co Nakagawa Seikodo Co Sinopharm Medicine Holding Beijing Huahong Ushioda Sagokudo Yakuhin Co Ministry of Commerce [China] Mitsubishi Napp Pharmaceutical Group National Association of Boards of Pharmacy (NABP) [US] National Health Service (NHS) [UK] Novartis Novo Nordisk Pfizer Pharmaceutical Security Institute (PSI) [US] Polish Pharmaceutical Chamber Polska Grupa Farmaceutyczna Profarma Prosper Protek ratiopharm Rite-Aid Roche Rosta Pharmaceutical Group Sanacorp sanofi-aventis Shanghai Pharmaceutical Group SIA International Sigma Pharmaceuticals Sincamesp [Brazil] State Food and Drug Administration (SFDA) [China] Suzuken and its subsidiaries: Astis Co Jingu Yakuhin Co Nakano Yakuhin Co Sanki Shanghai Suzuken Huzhong Pharmaceutical Shoyaku Co Suzuken Iwate Co Suzuken Okinawa Yakuhin Co Target Teva Pharmaceuticals The Phoenix Group and its subsidiaries: Amedis-UE [Switzerland] Apokjeden Group [Norway] Brocacef Holding [The Netherlands] Gruppo Comifar [Italy] Libra [Bulgaria] Nomeco [Denmark] Numark [UK] Phoenix Arzeiwarengro?handlung [Austria] Phoenix Farmacija [Croatia] Phoenix Lékárensky [Czech Republic] Phoenix Healthcare Distribution [UK] Phoenix Pharma [France/Hungary/Serbia] Phoenix Pharma Polska [Poland] Phoenix Pharmahandel [Germany] Phoenix Zdravotnícke zasobovanie [Slovakia] Rowlands [UK] Tamro [Sweden] SIA Tamro [Latvia] Tamro Suomi [Finland] Tamro Eesti [Estonia] UAB Tamro [Lithuania] Toho Holdings Torfarm United Nations (UN) Walgreens Walmart Wyeth Pharmaceuticals (now part of Pfizer) [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 1.1 Overview of the Study 1.2 Chapter Breakdown 1.3 Research and Analysis Methods 2. Introduction to the Industry and Market 2.1 The Role of Pharmaceutical Wholesalers 2.1.1 Full-Line Wholesalers (FLWs) 2.1.2 Short-Line Wholesalers (SLWs) 2.2 The Chain of Distribution 2.2.1 Secondary Wholesalers 2.2.2 Direct-to-Pharmacy 2.2.3 Pharmacy Benefit Managers 2.3 Generating Revenue and Profit 2.3.1 Forward Buying 2.3.2 Fee-for-Service 2.3.2.1 Inventory Management Agreements 2.3.3 Discounts 2.3.4 Reimbursement and Wholesalers 2.3.5 Clawback 2.3.6 Parallel Trade 3. The World Pharmaceutical Wholesale and Distribution Market 2011-2021 3.1 The World Market in 2009 3.2 World Market Forecast 2011-2021 3.3 The US 3.3.1 An Increase in Fee-for-Service Activity 3.3.2 US Market Forecast 2011-2021 3.4 Europe 3.4.1 Differences between the US and Europe 3.4.1.1 State-Funded Healthcare and Reimbursement 3.4.2 European Market Forecast 2011-2021 3.4.3 Germany 3.4.3.1 Healthcare Reform 3.4.3.2 Market Forecast 2011-2021 3.4.4 France 3.4.4.1 Market Forecast 2011-2021 3.4.5 Spain 3.4.5.1 Market Forecast 2011-2021 3.4.6 The UK 3.4.6.1 Price Cuts 2009-2010 3.4.6.2 Market Forecast 2011-2021 3.4.7 Italy 3.4.7.1 Market Forecast 2011-2021 3.5 Japan 3.5.1 Drug Pricing and Performance Fees 3.5.2 Market Forecast 2011-2021 3.6 China 3.6.1 Leading Companies 2009-2010 3.6.2 Recent Market Developments 3.6.3 Market Forecast 2011-2021 3.7 Brazil 3.7.1 Leading Companies 2009-2010 3.7.2 Market Forecast 2011-2021 3.8 Russia 3.8.1 Market Trends 3.8.2 Market Forecast 2011-2021 3.9 Regional Market Shares 2011-2021 4. Leading Wholesalers in the Global Market 2011-2021 4.1 Revenue vs. Profit 4.1.1 Profit Margins 2009 4.2 Leading Companies Market Forecast 2011-2021 4.3 McKesson 4.3.1 Recent Performance 4.3.2 Future Strategies 4.3.3 Revenue Forecast 2011-2021 4.4 Cardinal Health 4.4.1 Segment Reorganisation 4.4.2 Recent Performance 4.4.3 Future Strategies 4.4.4 Revenue Forecast 2011-2021 4.5 AmerisourceBergen 4.5.1 Recent Performance 4.5.2 Future Strategies 4.5.3 Revenue Forecast 2011-2021 4.6 The Phoenix Group 4.6.1 Recent Performance 4.6.2 The Tamro Group 2009-2010 4.6.3 Future Strategies 4.6.4 Revenue Forecast 2011-2021 4.7 Celesio 4.7.1 Recent Performance 4.7.2 Future Strategies 4.7.3 Revenue Forecast 2011-2021 4.8 Alfresa Holdings 4.8.1 Recent Performance 4.8.2 Future Strategies 4.8.3 Revenue Forecast 2011-2021 4.9 Medipal 4.9.1 Recent Performance 4.9.2 Future Strategies 4.9.3 Revenue Forecast 2011-2021 4.10 Alliance Boots 4.10.1 Recent Performance 4.10.2 Future Strategies 4.10.3 Revenue Forecast 2011-2021 4.11 Suzuken 4.11.1 Recent Performance 4.11.2 Future Strategies 4.11.3 Revenue Forecast 2011-2021 5. Qualitative Analysis of the Market 2011-2021 5.1 SWOT Chart for the Pharmaceutical Wholesale and Distribution Market 2011-2021 5.2 Strengths 5.2.1 Large Companies Dominate the Market 5.2.2 Wholesalers Do More than Deliver Drugs 5.2.2.1 Pre-Wholesaling 5.3 Weaknesses 5.3.1 Counterfeiting 5.3.2 Low Margins 5.4 Opportunities 5.4.1 Increased Demand for Pharmaceuticals 5.4.2 Generics 5.4.3 Globalisation 5.5 Threats 5.5.1 Direct-to-Pharmacy (DTP) 5.5.1.1 DTP in Europe 5.5.1.2 The UK 5.5.1.3 Poland 5.5.1.4 DTP in Australia 5.5.1.5 Further Expansion 5.5.2 Healthcare Budget Cuts 5.5.3 Diversion and Re-importation 5.5.4 Supermarket Pharmacies 5.5.4.1 Case Study: Walmart 6. Pharmaceutical Wholesale Industry Trends 2011-2021 6.1 Combating Counterfeit Medicines 6.1.1 The US and E-Pedigree 6.1.2 European Pedigree Legislation 6.1.3 Anti-Counterfeiting Strategies in Other Markets 6.1.4 Issues in Serialisation for Wholesalers 6.2 Growth in Specialty Pharmaceuticals 6.3 Industry Consolidation 6.4 Chain Pharmacies and Vertical Integration 7. Opinions from Our Survey 7.1 Professor David Taylor, Professor of Pharmaceutical and Public Health Policy, University of London 7.1.1 The Purpose of DTP 7.1.2 The Impact of DTP on Pharmacies 7.1.3 Changes to Drug Pricing in the UK 7.1.4 DTP and the Patient 7.1.5 Wholesale Trends Across Europe 7.2 Dr Heinz Kobelt, Secretary-General, European Association of Euro-Pharmaceutical Companies (EAEPC) 7.2.1 Benefits of Parallel Trade 7.2.2 Generics and Parallel Trade 7.2.3 Parallel Traders Combating Counterfeiting 7.2.4 The DTP Model 8. Conclusions 8.1 There Will Be Steady Growth in Developed Markets 8.1.1 Generics Will Threaten Revenues 8.1.2 Manufacturers Will Deliver Direct More Regularly 8.1.3 There Will Be Greater Demand for Specialty Medicines 8.2 Growth Will Be Faster in Emerging Markets 8.2.1 Consolidation Will Drive Growth 8.3 Anti-Counterfeiting Demands Will Add to Wholesalers' Costs [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 2.1 Prevalence of the DTP Model in the UK, 2011 Table 3.1 Global Pharmaceutical Wholesale and Distribution Market by Country, 2009 Table 3.2 Global Pharmaceutical Wholesale Market Forecast, 2009-2021 Table 3.3 Global Market Drivers and Restraints, 2011-2021 Table 3.4 US Pharmaceutical Wholesale and Distribution Market by Company, 2009 Table 3.5 US Market Drivers and Restraints, 2011-2021 Table 3.6 European Pharmaceutical Wholesale and Distribution Market by Country, 2009 Table 3.7 How Price Controls Vary Across Europe, 2010 Table 3.8 European Market Drivers and Restraints, 2011-2021 Table 3.9 European Pharmaceutical Wholesale Market Forecast, 2009-2021 Table 3.10 German Market Drivers and Restraints, 2011-2021 Table 3.11 French Market Drivers and Restraints, 2011-2021 Table 3.12 Spanish Market Drivers and Restraints, 2011-2021 Table 3.13 UK Pharmaceutical Wholesale and Distribution Market by Company, 2009 Table 3.14 UK Market Drivers and Restraints, 2011-2021 Table 3.15 Italian Market Drivers and Restraints, 2011-2021 Table 3.16 Japanese Points of Delivery, 2011 Table 3.17 Japanese Pharmaceutical Wholesale and Distribution Market, 2009 Table 3.18 Global Population Aged Over 65, 2009-2025 Table 3.19 Japanese Market Drivers and Restraints, 2011-2021 Table 3.20 Chinese Market Drivers and Restraints, 2011-2021 Table 3.21 Brazilian Market Drivers and Restraints, 2011-2021 Table 3.22 Russian Pharmaceutical Wholesale and Distribution Market, 2009 Table 3.23 Russian Market Drivers and Restraints, 2011-2021 Table 4.1 Leading Companies in the Market, 2009 Table 4.2 Company Year End Revenues, 2009 Table 4.3 Profit Margins Reported by Leading Companies, 2009 Table 4.4 Market Leaders: Drivers and Restraints, 2011-2021 Table 4.5 Pharmaceutical Wholesale Market Leaders: Forecast, 2009-2021 Table 4.6 McKesson Pharmaceutical Wholesale Revenue by Country, 2009 Table 4.7 McKesson Pharmaceutical Wholesale Revenue and Gross Profit by Quarter, 2009 Table 4.8 McKesson Wholesale Revenue Forecast, 2009-2021 Table 4.9 Cardinal Health's Bulk and Non-bulk Orders, 2009-2010 Table 4.10 Cardinal Health Wholesale Revenue Forecast, 2009-2021 Table 4.11 AmerisourceBergen Pharmaceutical Distribution Revenue and Gross Profit by Quarter, 2009 Table 4.12 AmerisourceBergen Pharmaceutical Distribution Revenue and Gross Profit, Q1-Q3 2010 Table 4.13 AmerisourceBergen Wholesale Revenue Forecast, 2009-2021 Table 4.14 The Phoenix Group Wholesale Subsidiaries, 2010 Table 4.15 The Phoenix Group Revenue and Gross Profit, February-October 2009-2010 Table 4.16 Tamro Group Revenue, 2009-2010 Table 4.17 The Phoenix Group Wholesale Revenue Forecast, 2009-2021 Table 4.18 Celesio Wholesale Subsidiaries, 2010 Table 4.19 Celesio Wholesale Revenue by Country, 2009 Table 4.20 Celesio Wholesale Revenue Forecast, 2009-2021 Table 4.21 Alfresa Wholesale Subsidiaries, 2010 Table 4.22 Alfresa Wholesale Revenue and Operating Income by Quarter, 2009 Table 4.23 Alfresa Wholesale Revenue Forecast, 2009-2021 Table 4.24 Medipal Wholesale Revenue and Operating Income by Quarter, 2009 Table 4.25 Medipal Wholesale Revenue and Operating Income, Q1-Q3 2010 Table 4.26 Medipal Wholesale Revenue Forecast, 2009-2021 Table 4.27 Alliance Boots Wholesale Revenue by Country, 2009 Table 4.28 Alliance Boots Wholesale Revenue Forecast, 2009-2021 Table 4.29 Suzuken Wholesale Revenue and Operating Income by Quarter, 2009 Table 4.30 Suzuken Wholesale Revenue and Operating Income, Q1-Q3 2010 Table 4.31 Suzuken Wholesale Revenue Forecast, 2009-2021 Table 5.1 SWOT Chart for the Pharmaceutical Wholesale and Distribution Market, 2011-2021 Table 5.2 Revenues for Leading Wholesalers and Manufacturers, 2009 Table 5.3 Regional Split of Counterfeiting Incidents, 2009 Table 5.4 Global Recorded Incidents of Counterfeit Medicines, 2002-2009 Table 5.5 Strengths and Weaknesses of the DTP Model Table 8.1 Global Pharmaceutical Wholesale Market Shares by Country, 2009, 2015 and 2021 Table 8.2 US Patent Expiries for Leading Small Molecule Drugs, 2010-2012 Figure 2.1 Traditional Routes of Drug Distribution, 2011 Figure 2.2 CVS Caremark Revenue by Segment, 2009 Figure 3.1 Global Pharmaceutical Wholesale and Distribution Market by Country, 2009 Figure 3.2 Global Pharmaceutical Wholesale Market Forecast, 2009-2021 Figure 3.3 US Pharmaceutical Wholesale and Distribution Market by Company, 2009 Figure 3.4 US Pharmaceutical Wholesale Market Forecast, 2009-2021 Figure 3.5 European Pharmaceutical Wholesale and Distribution Market by Country, 2009 Figure 3.6 European Pharmaceutical Wholesale Market Forecast, 2009-2021 Figure 3.7 German Pharmaceutical Wholesale Market Forecast, 2009-2021 Figure 3.8 French Pharmaceutical Wholesale Market Forecast, 2009-2021 Figure 3.9 Spanish Pharmaceutical Wholesale Market Forecast, 2009-2021 Figure 3.10 UK Pharmaceutical Wholesale and Distribution Market by Company, 2009 Figure 3.11 UK Pharmaceutical Wholesale Market Forecast, 2009-2021 Figure 3.12 Italian Pharmaceutical Wholesale Market Forecast, 2009-2021 Figure 3.13 Japanese Points of Delivery, 2011 Figure 3.14 Japanese Pharmaceutical Wholesale and Distribution Market, 2009 Figure 3.15 Changes to Japanese Drug Pricing, 2010 Figure 3.16 Aging Global Population, 2009-2025 Figure 3.17 Japanese Pharmaceutical Wholesale Market Forecast, 2009-2021 Figure 3.18 Chinese Pharmaceutical Wholesale Market Forecast, 2009-2021 Figure 3.19 Brazilian Pharmaceutical Wholesale Market Forecast, 2009-2021 Figure 3.20 Russian Pharmaceutical Wholesale and Distribution Market, 2009 Figure 3.21 Russian Pharmaceutical Wholesale Market Forecast, 2009-2021 Figure 3.22 Global Pharmaceutical Wholesale and Distribution Market by Country, 2015 Figure 3.23 Global Pharmaceutical Wholesale and Distribution Market by Country, 2021 Figure 4.1 Leading Companies in the Market, 2009 Figure 4.2 Pharmaceutical Wholesale Market Leaders: Forecast, 2009-2021 Figure 4.3 McKesson Pharmaceutical Wholesale Revenue by Country, 2009 Figure 4.4 McKesson Pharmaceutical Wholesale Revenue and Gross Profit by Quarter, 2009 Figure 4.5 McKesson Wholesale Revenue Forecast, 2009-2021 Figure 4.6 Cardinal Health Pharmaceutical Revenue by Company, FY 2009-2010 Figure 4.7 Cardinal Health's Bulk and Non-bulk Orders, FY 2009-2010 Figure 4.8 Cardinal Health Wholesale Revenue Forecast, 2009-2021 Figure 4.9 AmerisourceBergen Pharmaceutical Distribution Revenue by Quarter, 2009 Figure 4.10 AmerisourceBergen Wholesale Revenue Forecast, 2009-2021 Figure 4.11 The Phoenix Group Wholesale Revenue, February-October 2009-2010 Figure 4.12 Tamro Group Revenue, 2009-2010 Figure 4.13 The Phoenix Group Wholesale Revenue Forecast, 2009-2021 Figure 4.14 Celesio Wholesale Revenue by Country, 2009 Figure 4.15 Celesio Wholesale Revenue Forecast, 2009-2021 Figure 4.16 Alfresa Wholesale Operating Income Margin by Quarter, 2009 Figure 4.17 Alfresa Wholesale Revenue Forecast, 2009-2021 Figure 4.18 Medipal Wholesale Revenue by Quarter, 2009 Figure 4.19 Medipal Wholesale Operating Income Margin, Q1-Q3 2009-2010 Figure 4.20 Medipal Wholesale Revenue Forecast, 2009-2021 Figure 4.21 Alliance Boots Wholesale Revenue by Country, 2009 Figure 4.22 Alliance Boots Wholesale Revenue Forecast, 2009-2021 Figure 4.23 Suzuken Wholesale Revenue by Quarter, 2009 Figure 4.24 Suzuken Wholesale Operating Income Margin, Q1-Q3 2010 Figure 4.25 Suzuken Wholesale Revenue Forecast, 2009-2021 Figure 5.1 Revenues for Leading Wholesalers and Manufacturers, 2009 Figure 5.2 Regional Split of Counterfeiting Incidents, 2009 Figure 5.3 Global Recorded Incidents of Counterfeit Medicines, 2002-2009 Figure 5.4 Comparison of the Wholesaler and Direct-to-Pharmacy Routes Figure 6.1 Anti-Counterfeiting Strategies in the US and Europe, 2011 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
